News for Syros Pharmaceuticals, Inc. (0LC7.L)

Rege Nephro's acquisition of Tamibarotene-related assets from Syros Pharmaceuticals (SYRS) marks a significant expansion in its strategic portfolio, particularl

Rege Nephro has completed the acquisition of significant clinical and non-clinical assets associated with Tamibarotene from Syros Pharmaceuticals (SYRS). This t

Rege Nephro acquires Tamibarotene-related assets from Syros Pharmaceuticals (SYRS) for U.S. clinical trials. Tamibarotene (RN-014) is currently in Phase

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025.

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded ...

U.S. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket trading.

US. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket trading.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the ”œCompany”) today announced that its Board of Directors (the ”œBoard”) has approved and the Company intend

Significant Transaction by Avidity Partners Management LP (Trades, Portfolio) On December 31, 2024, Avidity Partners Management LP (Trades, Portfolio) executed

Transaction Overview On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a significant transaction involving Syros Pharmaceutic

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11%

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Wednesday. The Dow traded up 0.34% to 44,059.95 while the...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Wednesday. The Dow traded up 0.44% to 44,103.23 whil...

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.1% on Wednesday. Following the market opening Wednesday, the Dow traded up 0.1...

Shares of Rocket Lab USA, Inc. RKLB rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results. ...

Revenue: No revenue recognized in Q3 2024, compared to $3.8 million in Q3 2023.R&D Expenses: $20.5 million in Q3 2024, down from $28.3 million in Q3 2023.G&A E

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Syros Pharmaceuticals, Inc (NASDAQ:SYRS) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ETCompany ParticipantsKaren Hunady - Director of Investor...